Znanstveni rad - Izvorni znanstveni rad
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Frontiers in Pharmacology, 11 (2021); 591134. https://doi.org/10.3389/fphar.2020.591134

Moorkens, Evelien; Godman, Brian; Huys, Isabelle; Hoxha, Iris; Malaj, Admir; Keuerleber, Simon; Stockinger, Silvia; Mörtenhuber, Sarah; Dimitrova, Maria; Tachkov, Konstantin; Vončina, Luka; Vlahović Palčevski, Vera; Achniotou, Gnosia; Slabý, Juraj; Popelková, Leona; Kohoutová, Kateřina; Bartels, Dorthe; Laius, Ott; Martikainen, Jaana E.; Selke, Gisbert W.; Kourafalos, Vasileios; Magnússon, Einar; Einarsdóttir, Rannveig; Adams, Roisín; Joppi, Roberta; Allocati, Eleonora; Jakupi, Arianit; Viksna, Anita; Greičiūtė-Kuprijanov, Ieva; Vella Bonanno, Patricia; Suttorp, Vincent; Melien, Øyvind; Plisko, Robert; Mardare, Ileana; Meshkov, Dmitry; Novakovic, Tanja; Fürst, Jurij; Zara, Corinne; Marković-Peković, Vanda; Grubiša, Nataša; Befrits, Gustaf; Puckett, Robert; Vulto, Arnold G. Više autora...

Citirajte ovaj rad

Moorkens, E., Godman, B., Huys, I., Hoxha, I., Malaj, A., Keuerleber, S. ... Vulto, A. G. (2021). The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology, 11.. doi: 10.3389/fphar.2020.591134

Moorkens, Evelien, et al. "The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures." Frontiers in Pharmacology, vol. 11, 2021. https://doi.org/10.3389/fphar.2020.591134

Moorkens, Evelien, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, et al. "The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures." Frontiers in Pharmacology 11 (2021). https://doi.org/10.3389/fphar.2020.591134

Moorkens, E., et al. (2021) 'The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures', Frontiers in Pharmacology, 11. doi: 10.3389/fphar.2020.591134

Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, i sur.. The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology [Internet]. 2021. [pristupljeno 18.10.2021.];11. doi: 10.3389/fphar.2020.591134

E. Moorkens, et al., "The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures", Frontiers in Pharmacology, vol. 11, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:267790. [Citirano: 18.10.2021.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.